Artelo Biosciences, Inc.
NASDAQ: ARTLW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory D. Gorgas
- Employees
- 5
- Headquarters
- Solana Beach, United States
- IPO year
- 2019
- Market cap
- $13.1K
- Website
- https://www.artelobio.com
Loading ARTLW…
Loading profile data…Frequently asked questions about ARTLW
What does Artelo Biosciences, Inc. (ARTLW) do?
Artelo Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing and commercializing therapeutic agents that interact with the endocannabinoid system. The company's portfolio of drug candidates features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is currently undergoing Phase...
Where does ARTLW trade?
Artelo Biosciences, Inc. (ARTLW) trades on the NASDAQ Capital Market.
What sector is ARTLW in?
Artelo Biosciences, Inc. (ARTLW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Artelo Biosciences, Inc.?
Gregory D. Gorgas is the chief executive officer of Artelo Biosciences, Inc. (ARTLW).
Where is Artelo Biosciences, Inc. headquartered?
Artelo Biosciences, Inc. is headquartered in United States.
Does ARTLW pay a dividend?
Artelo Biosciences, Inc. (ARTLW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARTLW go public?
Artelo Biosciences, Inc. (ARTLW) completed its initial public offering in 2019.